Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade

Abstract

Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.

Keywords

• immunotherapy
• anthracycline
• lung cancer